CXCL4 Variant 1 Human
Description
The CXCL4 Variant-1 is fused to 6xHis tag at N-Terminus and purified by standard chromatography techniques.
Product Specs
Platelet factor-4 (PF4) is a protein composed of 70 amino acids that is released from activated platelets' alpha-granules. Its primary function appears to be the neutralization of molecules found on the endothelial surface of blood vessels. This action inhibits the activity of local antithrombin III, thereby promoting coagulation. PF4 acts as a potent chemoattractant for neutrophils and fibroblasts, suggesting its involvement in inflammatory processes and wound healing. Human PF4 is utilized in research to investigate induced thrombocytopenia and as an inhibitor of angiogenesis in tumor therapy.
Product Science Overview
PF-4 is a 70-amino acid protein that binds with high affinity to heparin. Its primary physiological role is to neutralize heparin-like molecules on the endothelial surface of blood vessels, thereby inhibiting local antithrombin activity and promoting coagulation . PF-4 is also a strong chemoattractant for neutrophils and fibroblasts, suggesting a role in inflammation and wound repair .
Platelet Factor-4 Variant 1 (PF4V1), also known as CXCL4L1, is a natural non-allelic gene variant of PF-4. This variant has been shown to have significant anti-angiogenic properties, meaning it can inhibit the formation of new blood vessels . This property makes PF4V1 particularly interesting in the context of cancer research, as it can potentially inhibit tumor growth and metastasis by preventing angiogenesis .
Recombinant PF4V1 is a form of the protein that is produced through recombinant DNA technology. This involves inserting the gene that codes for PF4V1 into a host organism, such as bacteria or yeast, which then produces the protein. The recombinant protein can be purified and used for various research and therapeutic purposes .
PF4V1 has shown promise in inhibiting the growth and metastasis of melanoma and lung carcinoma by preventing angiogenesis . It has been found to be more effective than PF-4 in various test systems, including wound-healing and migration assays for microvascular endothelial cells . Additionally, PF4V1 has been shown to reduce tumor growth and microvasculature more efficiently than PF-4 in animal models .
The anti-angiogenic properties of PF4V1 make it a potential candidate for cancer therapy. By inhibiting the formation of new blood vessels, PF4V1 can potentially starve tumors of the nutrients and oxygen they need to grow and spread . This makes it a promising target for the development of new cancer treatments.
